[1] Yip TF, Wond VWS, Chan HLY, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China.Gastroenterology,2020,158(1):215-225.e6.
[2] Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut,2014,63: 1943-1950.
[3] Murata K, Asano M, Matsumoto A, et al. Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut,2018,67:362-371.
[4] Wong GL, Chan HL, Tse YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol,2018,69: 793-802.
[5] Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean nationwide cohort study. JAMA Oncol,2019,5:30-36.
[6] Kim SU, Seo YS, Lee HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea. J Hepatol, 2019,71: 456-464.
[7] Lee SW, Kwon JH, Lee HL. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: A large scale, propensity score analysis. Gut,2019; in press.
[8] Hsu YC, Wong GL, Chen CH, et al. Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol,2020,115(2):271-280.
[9] Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Similar risk of hepatocellular carcinoma (HCC) development during long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. Hepatology,2019,70 (Suppl.): 286A.
[10] Pol S, ANRS/AFEF HEPATHER Study Group. Tenofovir versus entecavir in HBV chronic infection: impact on HCC and other liver-related complications occurrences. Hepatology,2019,70 (Suppl.): 129A.
[11] Kim WR, Telep L, Lu M, et al. Risk of incident hepatocellular carcinoma in hepatitis Binfected patients treated with tenofovir disoproxil fumarate versus entecavir: a US administrative claims analysis. Hepatology,2019,70 (Suppl.): 302A-303A. |
